Join to view full profile
808 S 52nd StRogers, AR 72758
Phone+1 479-936-9900
Fax+1 479-587-1366
Dr. Bradford is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1986 - 1989
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1983 - 1986
University of Arkansas For Medical Sciences College of MedicineClass of 1983
Certifications & Licensure
AR State Medical License 1983 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2013-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2013-2017
Clinical Trials
- Single Arm on the Tolerability of Weekly Nab-paclitaxel Start of enrollment: 2013 Jun 25
Publications & Presentations
PubMed
- 2 citationsIncreased Utilization of Low-Dose CT for Lung Cancer Screening at an Arkansas Community Oncology Clinic.Edgar T Ellis, Michael A Bauer, J Thaddeus Beck, Daniel S Bradford, Joanna Thompson
Journal of the American College of Radiology. 2024-06-01 - 12 citationsNab-paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapyJared Weiss, Nathan A. Pennell, Allison M. Deal, Daniel Morgensztern, Daniel S. Bradford
Cancer. 2020-03-01 - 48 citationsAn open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).Mark M. Awad, Quincy Chu, Leena Gandhi, Joe Stephenson, Ramaswamy Govindan
Lung Cancer. 2017-02-01
Press Mentions
NWA Cancer Treatment Group Participated in Successful, Annual Screening and Care ConferenceNovember 3rd, 2017
NWA Cancer Treatment Group to Participate in 3rd Annual Lung Cancer Alliance ConferenceOctober 4th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










